Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in Adult Recurrent or Refractory Medulloblastoma
NCT00939484Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2009
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in medulloblastoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response (CR+PR) Sustained for >= 8 Weeks up to 12 months. Started Jun 2009; status: completed.
02
Drugs
vismodegib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT00939484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939484.